Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering

Volker Spindler, … , Enno Schmidt, Jens Waschke


In pemphigus vulgaris, a life-threatening autoimmune skin disease, epidermal blisters are caused by autoantibodies primarily targeting desmosomal cadherins desmoglein 3 (DSG3) and DSG1, leading to loss of keratinocyte cohesion. Due to limited insights into disease pathogenesis, current therapy relies primarily on nonspecific long-term immunosuppression. Both direct inhibition of DSG transinteraction and altered intracellular signaling by p38 MAPK likely contribute to the loss of cell adhesion. Here, we applied a tandem peptide (TP) consisting of 2 connected peptide sequences targeting the DSG adhesive interface that was capable of blocking autoantibody-mediated direct interference of DSG3 transinteraction, as revealed by atomic force microscopy and optical trapping. Importantly, TP abrogated autoantibody-mediated skin blistering in mice and was effective when applied topically. Mechanistically, TP inhibited both autoantibody-induced p38 MAPK activation and its association with DSG3, abrogated p38 MAPK-induced keratin filament retraction, and promoted desmosomal DSG3 oligomerization. These data indicate that p38 MAPK links autoantibody-mediated inhibition of DSG3 binding to skin blistering. By limiting loss of DSG3 transinteraction, p38 MAPK activation, and keratin filament retraction, which are hallmarks of pemphigus pathogenesis, TP may serve as a promising treatment option.

Find the latest version:

http://jci.me/60139/pdf
In pemphigus vulgaris, a life-threatening autoimmune skin disease, epidermal blisters are caused by autoantibodies primarily targeting desmosomal cadherins desmoglein 3 (DSG3) and DSG1, leading to loss of keratinocyte cohesion. Due to limited insights into disease pathogenesis, current therapy relies primarily on nonspecific long-term immunosuppression. Both direct inhibition of DSG transinteraction and altered intracellular signaling by p38 MAPK likely contribute to the loss of cell adhesion. Here, we applied a tandem peptide (TP) consisting of 2 connected peptide sequences targeting the DSG adhesive interface that was capable of blocking autoantibody-mediated direct interference of DSG3 transinteraction, as revealed by atomic force microscopy and optical trapping. Importantly, TP abrogated autoantibody-mediated skin blistering in mice and was effective when applied topically. Mechanistically, TP inhibited both autoantibody-induced p38 MAPK activation and its association with DSG3, abrogated p38 MAPK-induced keratin filament retraction, and promoted desmosomal DSG3 oligomerization. These data indicate that p38 MAPK links autoantibody-mediated inhibition of DSG3 binding to skin blistering. By limiting loss of DSG3 transinteraction, TP may serve as a promising treatment option.

**Introduction**

Pemphigus vulgaris (PV) is a life-threatening blistering disease histopathologically characterized by acantholysis, i.e., cleft formation within the epidermis or mucous membranes (1). The disease is caused by autoantibodies predominantly directed against keratinocyte surface antigens. Autoantibodies against the cadherin-type adhesion molecules desmoglein 1 (DSG1) and DSG3 are well established to be both necessary and sufficient to induce cell dissociation both in vivo and in vitro (2). Recently, desmocollin 3 (DSC3) was suggested as another relevant cadherin-type antigen in pemphigus (3). Of note, other autoantibodies against nonadhesive molecules such as acetylcholine receptors are present in PV but their pathophysiological significance is not fully understood (4, 5).

DSGs are part of the core complex of desmosomes (6, 7). These distinct cell adhesion sites are abundant in tissues that are exposed to high degrees of mechanical stress, such as the epidermis or the heart muscle. DSGs, together with DSCs, are transmembrane proteins which mediate adhesion by transinteracting with cadherins of the opposing cell. Both homophilic (e.g., DSG3-DSG3) and heterophilic (e.g., DSC3-DSG1) transinteraction have been shown (8–12). Within the desmosome, DSGs and DSCs are anchored to the intracellular plaque proteins plakoglobin, plakophilins, and desmoplakin, the latter of which mediates connection to the intermediate filament cytoskeleton. Thus, desmosomes are essential for the integrity of the specific tissues.

The main pemphigus variant is PV. Patients with autoantibodies against DSG3 typically suffer from mucous membrane erosions, whereas patients with additional DSG1 autoantibodies suffer from both mucous membrane and skin lesions (13). Regarding the pathogenic mechanisms underlying the typical suprabasal acantholysis in PV, 2 main dogmata exist. One attributes loss of cell adhesion solely to direct inhibition of DSG transinteraction by binding of PV Abs (14, 15). This is supported by atomic force microscopy (AFM) experiments demonstrating that under cell-free conditions, IgG fractions of PV patients interfere with DSG3 transinteraction (8, 9). Recently, it was reported that pathogenicity of DSG3 Abs relies on the existence of a consensus domain, which includes a tryptophan residue that may interact with the hydrophobic binding pocket necessary for transinteraction of DSG molecules (16).

Another hypothesis explains cell dissociation merely as a result of cell-signaling events altered by PV-IgG. Indeed, a broad array of signaling events including protein kinase C activation, plakoglobin shuttling, epidermal growth factor signaling, Rho-GTPase inhibition, and cAMP elevation has been described (17–23). A central step required for pemphigus pathogenesis appears to be p38 MAPK activation, which was shown to occur in vitro and in vivo as well as in patient skin lesions (18, 20, 24–26).

Despite the variety of possible therapeutic approaches under experimental conditions, the therapy of pemphigus patients still is based on long-term use of high-dose systemic corticosteroids in combination with other immunosuppressants including azathioprine, mycophenolate, cyclophosphamide, and more recently, rituximab (27, 28). Due to the frequently observed adverse reactions, novel and specific treatment options are highly needed.

Recently, we have characterized a DSG-specific peptide termed single peptide (SP) that interferes with transinteraction of DSG molecules in a cell-free system (29). Importantly, 2 linked SP...
Figure 1
TP blocked acantholysis in vivo. TP blocked macroscopic blistering (arrows) when injected into the back skin of neonatal mice (A) or applied topically (B). Processing of cryosections revealed typical suprabasal blistering under conditions of AK23 and PV1-IgG injections, but absence or minor blistering (arrows) under conditions of topical TP treatment (C, upper panels). Lower panels demonstrate proper IgG deposition within the epidermis following injection of AK23 or PV-IgG and absence of staining in control-IgG–injected animals. Dashed lines represent dermal-epidermal junction. Scale bar: 50 μm (inserts, x2 magnification). Evaluation of blister size in serial sections under conditions of TP application 2 hours prior to Ab injection (D) and 6 hours after Ab injection (E). Serial sections of skin samples were evaluated for cleft length and sorted into a score ranging from 0 to 4 as detailed in Methods. Every data point represents 1 injected animal; higher values indicate stronger blistering. *P < 0.05 Ab injection vs. respective Ab injection + TP.
yielding a tandem peptide (TP) abolished loss of transinteraction induced by PV-IgG in vitro. Here, we extended these studies to the in vivo situation in a pemphigus mouse model and investigated the mechanisms underlying the protective effect of TP.

Results

TP abrogated autoantibody-mediated interference of DSG3 transinteraction and blocked acantholysis in vivo. Previously, we designed and extensively characterized a peptide effectively blocking autoantibody-induced loss of DSG3 transinteraction in vitro, which we have termed TP (29). It consists of 2 linked single peptides which, when applied unlinked, interfere with DSG transinteraction (29). To prove the efficacy of TP to block the effect of the Abs used in this study, we applied AFM on recombinant DSG3 molecules and optical trapping of DSG3-coated microbeads on HaCaT keratinocytes (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI60139DS1). We used AK23, a well-characterized monoclonal DSG3 Ab against the N-terminal adhesive interface of DSG3 derived from an active pemphigus mouse model (30) and an IgG fraction of a PV patient (PV1-IgG) suffering from mucocutaneous disease with autoantibodies against DSG3 and DSG1. Both loss of DSG3 interaction and reduced binding of DSG3-coated microbeads after 30 minutes of AK23 or PV1-IgG incubation were ameliorated by 30 minutes of pretreatment with TP.

Next, we applied TP in vivo. We used the neonatal pemphigus mouse model and injected the back skin of newborn Balb/c mice with AK23 (100 μg/mouse) or PV1-IgG (300 μg/mouse). PV1-IgG induced gross blisters at the injection site upon application of shear stress on the back skin (Nikolsky sign) (Figure 1A). Interestingly, selectively targeting DSG3 by AK23 also was effective to induce Nikolsky-positive blisters in a dose-dependent manner (Figure 1A and Supplemental Figure 2A). However, 50 μl TP pre-injection (20 μmol/l) 2 hours before application of Abs abolished gross blistering (Figure 1A and Table 1). To further explore the therapeutic potential of TP, the molecule was also applied topically because cutaneous injection of TP is obviously not a feasible approach for the treatment of pemphigus patients. Although the penetration of peptides through the epidermis is limited and depends on a variety of factors, such as size or polarity, successful delivery, for instance, for insulin, has been demonstrated (31). We therefore applied 2 nmol of TP in linimentum aquosum ointment (a 2-fold dose compared with the injection experiments to account for a potential loss by epidermal penetration) on the back of neonatal mice 2 hours before control-IgG, AK23, and PV1-IgG were injected, respectively. These mice were compared with mice that received the ointment without TP followed by injection of Abs. We confirmed that TP was able to penetrate the upper epidermal layers, as biotin-labeled TP was detectable within the epidermis (Supplemental Figure 2B). Macroscopically, blistering was absent in all but 1 mouse (Figure 1B and Table 1). Also histologically, blistering was drastically reduced (Figure 1C); however, small blisters were slightly more frequent compared with the animals injected with TP. The strictly suprabasal cleavage plane typical for PV was demonstrated by staining DSG3 in cryosections of the back skin (Figure 1C). Human IgG was visualized to guarantee proper Ab deposition (Figure 1C). TP did not pronouncedly affect AK23 or PV1-IgG binding to keratinocytes.

To more thoroughly investigate the effect of TP on suprabasal blister size, a detailed analysis of serial sections of skin samples was performed (Figure 1D) and a second IgG fraction was included (PV2-IgG). Gross blistering by PV2-IgG was prevented by TP similarly to AK23 and PV1-IgG. One section per 100 μm was stained and scored using a scale ranging from 0 to 4 as detailed in Methods until the complete sample was processed. All animals injected with control-IgG yielded a score of zero, as no blistering was evident. Following AK23, PV1-IgG, or PV2-IgG injection, scores of 3.3 ± 0.4, 2.5 ± 0.4, and 2.3 ± 0.5 were determined, respectively. In contrast, TP preinjection reduced scores to 0.7 ± 0.2 (AK23), 0.4 ± 0.2 (PV1-IgG), and 0.3 ± 0.2 (PV2-IgG). Topical treatment was slightly less effective, with values of 1.0 ± 0.5 (AK23) and 0.7 ± 0.3 (PV1-IgG). TP alone did not induce macroscopic or microscopic blisters, even when injected in 10-fold higher doses (200 μmol/l) (Supplemental Figure 2C).

To better mimic the situation in patients, we applied TP 6 hours after addition of autoantibody fractions. Similar to TP preinjection, TP post-treatment significantly reduced gross blistering (Table 1) and microscopic cleavage formation (Figure 1E) independently of whether applied by injection or topically.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Macroscopic blistering in the murine pemphigus model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TP pretreatment</td>
</tr>
<tr>
<td></td>
<td>No. mice with gross blisters</td>
</tr>
<tr>
<td>Control-IgG</td>
<td>0</td>
</tr>
<tr>
<td>AK23</td>
<td>7</td>
</tr>
<tr>
<td>AK23 + TP injected</td>
<td>0</td>
</tr>
<tr>
<td>AK23 + TP topical</td>
<td>1</td>
</tr>
<tr>
<td>PV1-IgG</td>
<td>8</td>
</tr>
<tr>
<td>PV1-IgG + TP injected</td>
<td>0</td>
</tr>
<tr>
<td>PV1-IgG + TP topical</td>
<td>0</td>
</tr>
<tr>
<td>PV2-IgG</td>
<td>3</td>
</tr>
<tr>
<td>PV2-IgG + TP injected</td>
<td>0</td>
</tr>
<tr>
<td>PV2-IgG + TP topical</td>
<td>0</td>
</tr>
</tbody>
</table>

*No. mice with gross blisters:* TP pretreatment vs. TP posttreatment, *p* < 0.05. Results from 6 mice in each group.
The monolayers were exposed to defined mechanical stress, and the resulting fragment numbers were quantified. In controls, fragment numbers were $3.2 \pm 1.1$. AK23, PV1-IgG, or PV2-IgG treatment for 24 hours increased fragment numbers to $28.0 \pm 5.4$, $55.7 \pm 10.6$, and $23.9 \pm 2.2$, respectively. Loss of cell adhesion was significantly reduced by simultaneous application of TP with fragment values of $9.9 \pm 3.4$ (AK23), $27.0 \pm 1.9$ (PV1-IgG), and $14.7 \pm 1.9$ (PV2-IgG). Autoantibody treatment for 48 hours yielded similar results. In a second set of experiments, we added TP 6 hours after starting the incubation with autoantibodies (Figure 2C). Under these conditions, TP also was effective in reducing fragment numbers from $20.3 \pm 1.9$ to $10.5 \pm 1.1$ (AK23), from $43.8 \pm 2.8$ to $25.8 \pm 1.0$ (PV1-IgG), and from $26.0 \pm 1.7$ to $13.1 \pm 2.4$ (PV2-IgG). Similar results were obtained when TP was

Figure 2
TP ameliorated fragmentation of DSG3 staining and cell dissociation induced by autoantibody application in vitro. (A) In cultured HaCaT keratinocytes, fragmentation of DSG3 staining induced by AK23, PV1-IgG, or PV2-IgG was reduced after 24 and 48 hours coincubation with TP. Cells incubated with either TP alone or SP did not demonstrate pronounced changes in the distribution of DSG3. Scale bar: 20 μm. Images are representative of at least 3 experiments. (B) Loss of cell adhesion induced by autoantibody treatment for 24 and 48 hours was ameliorated as detected by dispase-based dissociation assays ($n = 9–11$). Similar results were obtained when TP was applied 6 hours after addition of autoantibodies for 24 hours (C) or 24 hours after addition of autoantibodies for 48 hours (D). $n = 9$. $^* P < 0.05$. 

(Figure 2B).
added after 24 hours of a total of 48 hours incubation time with autoantibodies (Figure 2D). TP incubation alone in a 10-fold higher dose (200 μM) only slightly increased fragment numbers compared with autoantibody application (Supplemental Figure 3A). Taken together, these data demonstrate that TP efficiently prevented loss of cell adhesion in vitro and in vivo.

TP prevented p38 MAPK activation in response to autoantibodies in vitro and in vivo. It is still unclear whether direct inhibition of DSG transinteraction or changes in intracellular signaling patterns are the main cause for loss of intercellular adhesion (5, 13). Among the alterations of intracellular signaling molecules, phosphorylation of p38 MAPK at threonine residue 180 and tyrosine 182 is well established (24–26). Therefore, we investigated whether p38 MAPK phosphorylation plays a role in the protective effect of TP in HaCaT cells (Figure 3A). Both AK23 and PV1-IgG induced phosphorylation of p38 MAPK after 30 minutes. Band intensity was increased 1.8 ± 0.2–fold and 1.9 ± 0.2–fold compared with control cells. Interestingly, p38 MAPK activation was blocked by 30 minutes of preincubation of TP (1.3 ± 0.1–fold and 0.9 ± 0.3–fold of controls, respectively).

To further substantiate that specific disruption of DSG transinteraction triggered p38 MAPK activation, we used SP. In dissociation experiments with HaCaT monolayers, phosphorylation of p38 MAPK at threonine residue 180 and tyrosine 182 was well established (24–26). Therefore, we investigated whether p38 MAPK phosphorylation plays a role in the protective effect of TP in HaCaT cells (Figure 3A). Both AK23 and PV1-IgG induced phosphorylation of p38 MAPK after 30 minutes. Band intensity was increased 1.8 ± 0.2–fold and 1.9 ± 0.2–fold compared with control cells. Interestingly, p38 MAPK activation was blocked by 30 minutes of preincubation of TP (1.3 ± 0.1–fold and 0.9 ± 0.3–fold of controls, respectively).

Next, we analyzed samples of mice back skin 16 hours following injection of control-IgG, AK23, or PV1-IgG for p38 MAPK activation in Western blots. Compared with control-IgG, the amount of phosphorylated p38 MAPK (phospho–p38 MAPK) increased 2.17 ± 0.03–fold (AK23) and 1.77 ± 0.07–fold (PV1-IgG), respectively (Figure 3D). A 2-hour preinjection of TP significantly reduced the amount of phospho–p38 MAPK to 1.73 ± 0.09–fold of controls and 1.39 ± 0.12–fold of controls, respectively. We next injected SP into mice back skin. We did not detect intraepidermal blistering; however, fragmentation of DSG3 immunostaining was evident (not shown). In addition, SP injection increased p38 MAPK phosphorylation 2.0 ± 0.3–fold of that in controls (Figure 3E).

Since SP increased p38 MAPK phosphorylation and TP decreased phosphorylation induced by autoantibodies, it is reasonable to assume that loss of DSG binding triggers p38 MAPK signaling. An important mechanism for cadherin-mediated binding in general is the insertion of a conserved tryptophan residue at position 2 into a hydrophobic pocket of an opposing cadherin molecule often referred to as tryptophan swap (32–34). Therefore, we hypothesized that addition of tryptophan to the culture medium would have an effect on cell adhesion and p38 MAPK activation. Indeed, p38 MAPK phosphorylation was detectable when 1 μmol/l tryptophan was added for 30 minutes (Figure 4A). This was tryptophan specific, as another aromatic and hydrophobic amino acid, phenylalanine (1 μmol/l), had no effect. Next, we tested whether tryptophan interfered with DSG3 binding in AFM experiments (Figure 4B). Indeed, at concentrations of 1 μmol/l and 20 μmol/l, binding frequency was reduced to 0.75 ± 0.12
and 0.61 ± 0.10 of controls after 30 minutes, respectively. Furthermore, 30 minutes of TP pretreatment blocked tryptophan-induced loss of DSG binding (1.10 ± 0.09 of controls). Phenylalanine (20 μmol/l) had no effect (0.98 ± 0.09 of controls). Similarly, as measured by dissociation assays, tryptophan increased loss of HaCaT adhesion in a dose-dependent fashion, whereas phenylalanine had minor effects (Figure 4C and Supplemental Figure 3, B and C). Importantly, tryptophan-induced cell dissociation was significantly reduced by TP treatment (7.3 ± 1.0 compared with 2.8 ± 0.5 fragments). These data underscore the results from experiments using SP, indicating that p38 MAPK activation occurs in response to loss of DSG interaction.

**Autoantibody treatment induced activation of DSG3-associated p38 MAPK.** Since disruption of DSG3 binding led to activation of p38 MAPK, we next investigated whether DSG3 and p38 MAPK interact, which would indicate the existence of a signaling complex involving DSG3. Using proximity ligation assays (PLAs) for detecting close proximity of DSG3 and phospho–p38 MAPK, only few signals (i.e., molecules closer < 40 nm) were visible under control conditions (Figure 5A). However, after incubation with AK23 for 30 minutes, mean numbers of signals increased from 0.09 ± 0.04 per cell in controls to 1.00 ± 0.21 (Figure 5B). Importantly, tryptophan-induced cell dissociation was significantly reduced by TP treatment (7.3 ± 1.0 compared with 2.8 ± 0.5 fragments). These data underscore the results from experiments using SP, indicating that p38 MAPK activation occurs in response to loss of DSG interaction.

**TP inhibits autoantibody- and anisomycin-induced keratin filament retraction.** One of the hallmarks in pemphigus is the collapse of the intermediate filament cytoskeleton, which appears detached from desmosomes and clustered around the nucleus (35). Therefore, we investigated the effect of TP on keratin filament retraction (Figure 6A). Compared with controls, after both 24 and 48 hours of PV1-IgG incubation, intermediate filaments were detached from cell borders (visualized by E-cadherin staining). This effect was strongly reduced by simultaneous TP treatment. To quantitate these observations, the distance between the mass of intermediate filament bundles of opposing cells was measured, as indicated in Figure 6B. AK23, as well as both PV1-IgG and PV2-IgG, significantly increased the distance after 24 and 48 hours, and this was abrogated by TP (Figure 6C). In contrast, SP incubation significantly induced cytokeratin retraction after 24 hours, although less pronounced than after autoantibody incubation (Figure 6D).

It is known that keratin filament dynamics are regulated by p38 MAPK (36–38). To explore whether keratin filament retraction in this context is mediated by p38 MAPK, we used anisomycin to activate p38 MAPK in HaCaT cells. Indeed, treatment with 60 μmol/l anisomycin for 6 hours caused robust p38 MAPK activation (Figure 7A), pronounced keratin filament retraction (Figure 7, B and C), and cell dissociation (Figure 7D). These events were indeed mediated by p38 MAPK because they were abrogated by specific inhibition via SB202190 (30 μmol/l). As expected, TP treatment did not affect anisomycin-induced p38 MAPK phosphorylation (Figure 7A). However, TP effectively inhibited keratin filament retraction as well as cell dissociation. Thus, TP blocked keratin filament retraction and cell dissociation in response to both auto-
antibody- and anisomycin-mediated p38 MAPK activation. This result suggests that p38 MAPK regulates desmosomal adhesion partially via keratin filament anchorage and that desmosomal cadherin-mediated binding prevents collapse of the intermediate filament cytoskeleton also in part via control of p38 MAPK activity. To further investigate this hypothesis, we characterized the effects of TP on DSG3 arrangement on the keratinocyte cell surface. TP promoted oligomerization of DSG3 molecules within desmosomes.

We next investigated whether TP would inhibit autoantibody-mediated depletion of DSG3, which occurs in HaCaTs when grown for 3 days in high Ca2+ medium (39). However, no increased DSG3 levels were notable when TP was coincubated for either 24 or 48 hours with PV1-IgG or PV2-IgG compared with autoantibody treatment alone (Supplemental Figure 4).

Since DSG binding is generally rather weak, we next crosslinked HaCaT cell-surface proteins in vivo with the membrane-impermeable crosslinker ethylene glycol bis(sulfosuccinimidylsuccinate) (sulfo-EGS) (10) and subjected lysates to Western blotting to study oligomerization of DSG3 (Figure 8). Besides the band corresponding to monomeric DSG3 at a size of 130 kDa, we detected 1 band migrating at around 350 to 400 kDa. This band probably represents crosslinked cell-surface DSG3 molecules, since it was absent without application of sulfo-EGS (data not shown). Both bands were reduced to 0.48 ± 0.11 of controls (monomer) and 0.64 ± 0.13 (oligomer) when AK23 was applied for 24 hours (Figure 8A). Interestingly, coincubation of TP led to an increase of oligomeric DSG3 (1.16 ± 0.23 of controls), but not of monomeric DSG3 (0.48 ± 0.08 of controls). Similarly, tryptophan (1 μmol/l) reduced oligomers, which was inhibited by TP (Figure 8B).

To further investigate whether TP promoted oligomerization of DSG3 within desmosomes or within the nondesmosomal pool, we performed Triton X-100 extraction of HaCaT lysates. Both pools were depleted of oligomeric DSG3 by AK23; however, TP increased DSG3 oligomers mainly in the desmosomal pool (Figure 8C). Taken together, the data suggest that TP promoted oligomerization of DSG3 within desmosomes.

Discussion
In this study, we applied a TP consisting of 2 cyclized nonapeptides targeting the adhesive interface of DSGs in vivo. TP, which blocked loss of transinteraction following exposition to pemphigus autoantibodies, efficiently prevented skin blistering by AK23 and PV-IgG when injected intradermally into the back skin of neonatal mice. Most importantly, and for the first time, to our knowledge, this specific approach was also effective when applied topically, rendering it potentially applicable as a treatment option in pemphigus. In addition, TP served to further elucidate the mechanisms by which autoantibodies cause loss of cell cohesion. We targeted DSG3 transinteraction by different approaches and found that direct inhibition of DSG3 binding caused activation of p38 MAPK in vivo and in vitro as well as retraction of keratin filaments, both hallmarks of pemphigus pathogenesis that were blocked by TP. Furthermore, we showed that p38 MAPK associated with DSG3 and in this localization was activated in response to AK23. This indicates the existence of a DSG3-based signaling complex that controls intermediate filament cytoskeleton dynamics dependent on intercellular cohesion.

TP may serve as promising treatment option in pemphigus. Pemphigus is a severe autoimmune disease that potentially leads to death due to uncontrollable epidermal barrier defects and infections. Thus, a constant immunosuppression, commonly reached by steroid application, is pivotal and often necessary for long periods of time. Newer approaches, such as B cell depletion or intravenous application of high doses of IgG, are effective but not primarily applied yet. Thus, to prevent the severe side effects of unspecific immunosuppression, other steroid-sparing approaches are highly appreciated.
TP application abrogated both autoantibody-induced loss of DSG transinteraction and p38 MAPK activation. Thus, 2 main mechanisms underlying pemphigus pathogenesis, i.e., direct inhibition of DSG binding as well as altered intracellular signaling, were prevented by TP. This makes application of TP or similar substances a very attractive and specific therapeutic approach in PV therapy. A topical approach might indeed be feasible because some PV lesions tend to relapse at preferred sites, e.g., the scalp. Especially at these sites, application of TP may be beneficial. Moreover, since TP was also protective in vivo when applied after injection of autoantibodies, it is conceivable that application in developing lesions is effective too. Further studies need to determine and to optimize the delivery efficiency and potential toxicity in human skin.

DSG3 regulates p38 MAPK activity to control keratin filament dynamics. A relatively new concept proposes that desmosomal proteins, especially the desmosomal cadherins, modulate intracellular signaling events (40). It has been shown that DSG1 suppresses EGFR signaling in the more superficial epidermal layers (41). Furthermore, DSC2 has recently been demonstrated to prevent PI3K/Akt-mediated phosphorylation of β-catenin (42). Data from this study support this concept because TP, by promoting DSG transinteraction, blunted p38 MAPK activation in response to the DSG3-specific autoantibody AK23, indicating that DSG3 is involved in regulation of p38 MAPK activity. In line with this observation, SP, which prevents DSG transinteraction, increased p38 MAPK activation. Thus, most likely, loss of DSG transinteraction is the trigger for p38 MAPK activation, which is further underscored by our data showing that tryptophan, to block the tryptophan swap important for cadherin transinteraction (43), had the same effect. This places p38 MAPK activation downstream of direct inhibition of DSG3 binding in pemphigus. In this context, it is very interesting that p38 MAPK associates with DSG3 and plakoglobin and thus may form a DSG3-based signaling complex that is present under resting conditions. Upon autoantibody binding, DSG3-associated p38 MAPK is phosphorylated and thereby activated. The fact that, similarly to TP in this study, inhibition of p38 MAPK was found to prevent PV-IgG-induced loss of cell adhesion and skin blister-
ing both in vitro and in vivo (24, 25) suggests that a signaling loop exists in which p38 MAPK is activated by loss of DSG transinteraction, which in turn destabilizes desmosomal adhesion.

In this context, the cytoskeleton may play an important role. The intermediate filament network tethering desmosomes to the cell membrane has been demonstrated to disintegrate in response to p38 MAPK activation (36). Since a tight anchorage of intermediate filaments to the desmosomal complex is necessary for maintaining strong adhesion (44) and retraction of the intermediate filament network is a hallmark of pemphigus (35), p38 MAPK-mediated collapse of these cytoskeletal structures may be a central event for loss of cell adhesion. This idea is supported by the data showing that anisomycin-mediated p38 MAPK activation induced both keratin filament retraction and loss of cell adhesion.

However, it is noteworthy that TP, without affecting p38 MAPK activation in response to anisomycin, still was effective in abrogating keratin filament retraction and loss of cell adhesion. This observation indicates that desmosomal adhesion and intermediate filament cytoskeleton integrity are linked to each other in reciprocal fashion. Augmented oligomerization of desmosomal DSG3, which we detected in response to TP, may therefore increase intercellular adhesion not only directly but also by controlling keratin filament anchorage. Since TP reduced both autoantibody-induced p38 MAPK activation and autoantibody- and anisomycin-mediated keratin filament retraction, the data also raise the possibility that other signaling pathways involved in keratin filament retraction are modulated by DSG3 binding. It has been shown that a desmoplakin point mutation (Ser2849Gly) exhibited strongly increased binding to intermediate filaments and in addition rendered desmosomes super-adhesive (45), a state that also protects against loss of cell adhesion in pemphigus (39, 46). Since the desmoplakin point mutation is located within a PKC consensus sequence, one may speculate that PKC-mediated phosphorylation of desmoplakin may be involved in keratin filament retraction and this process may be modulated by TP via stabilization of DSG3 binding.

Nevertheless, p38 MAPK may regulate desmosomal adhesion independently of intermediate filaments. For example, p38 MAPK phosphorylation has been shown to alter organization of the actin cytoskeleton via heat shock protein 27 (24) and actin filament dynamics, especially within the peripheral junction-associated actin belt were shown to affect autoantibody-induced loss of cell adhesion (47).
Moreover, p38 MAPK has been demonstrated to be involved in autoantibody-induced DSG3 internalization in pemphigus (48).

Taken together, data from this study demonstrate that a topically administered approach to specifically targeting DSG-mediated binding not only is effective in limiting pemphigus autoantibody-induced skin blistering in vivo, but also serves as a good tool for studying the mechanisms underlying pemphigus pathogenesis.

**Methods**

**Test reagents.** The monoclonal DSG3 Ab AK23 (30) was purchased from Biozol and used at 75 μg/ml in vitro. PV sera were drawn from patients with active PV suffering from both oral and skin lesions. Both sera were tested by ELISA for DSG1 and DSG3 Abs (Table 2) and applied at 0.5 mg/ml in vitro. PV-IgG was purified as reported before (49). Anisomycin (Sigma-Aldrich) was applied at 60 μmol/l.

TP was characterized before (29) and synthesized by Bachem GmbH. It consisted of 2 so-called SP, with the sequence LNSMGQD corresponding to amino acids 81–86 of DSG1 mimicking a transinteracting DSG. Because of high sequence homology at this position for DSG1 and DSG3, SP is supposed to bind both isoforms (29). A cysteine residue was added to the C- and N-terminal ends, which were connected by disulfide bonds yielding a cyclized peptide. In the combined TP, 2 SP are interconnected by a flexible amino hexan linker interposed between 2 cysteine residues. TP was applied at 20 μmol/l, a concentration experimentally determined to block PV-IgG-mediated direct inhibition of DSG3 transinteraction (29). SP was applied at 200 μmol/l for topical treatment; 2 nmol TP in 100 mg limeninatum aquosum ointment per mouse was freshly prepared prior to usage. For some experiments, TP was labeled with sulfo-NHS-biotin (Thermo Fisher Scientific) according to the manufacturer’s instructions, dialyzed extensively afterwards to remove excess biotin, and applied topically. Tryptophan and phenylalanine were purchased from Sigma-Aldrich and applied at concentrations from 1 to 200 μmol/l.

**Neonatal mouse model.** Newborn Balb/C mice weighing 1.4–1.8 g were injected intradermally into the back skin with 50 μl PV1-IgG or PV2-IgG (6 mg/ml each), AK23 (2 mg/ml, 0.4 mg/ml, or 0.08 mg/ml), or control-IgG of a healthy donor (6 mg/ml) in PBS. SP was injected at 200 μmol/l (50 μl PBS). TP was preinjected at 20 μmol/l (in 50 μl PBS) 2 hours before injection of IgG fractions. Controls and IgG-only conditions received 50 μl of PBS 2 hours before. For some experiments, 2 nmol TP was mixed in 100 mg of limeninatum aquosum and applied as ointment on the back skin 2 hours before injection of IgG fractions. As controls, limeninatum aquosum was mixed with PBS and also applied 2 hours before. In another set of experiments, TP was either injected or applied topically 6 hours after injection of PV1-IgG or PV2-IgG. Sixteen hours after injection of autoantibodies, the injection site was exposed by a cryostat (Reichert-Jung) and frozen in liquid nitrogen. Parts of the samples were homogenized in Laemmli buffer with 10 strokes of a homogenizer and subjected to Western blotting experiments.

**Processing of cryosamples and scoring of blister size.** Samples were cut with a cryostat (Reichert-Jung). Every 100 μm, 2 sections were stained with 1% toluidine blue solution and evaluated for intraepidermal separation until the complete sample was processed. Each section was then evaluated and sorted in a scoring system according to the following guidelines: absence of intraepidermal separation, score 0; cleft size covering 1%–25% of total section length, score 1; cleft size between 26% and 50% of section length, score 2; cleft size between 51% and 75%, score 3; and cleft size over 75%, score 4. If different numbers were obtained within 1 sample, the highest number was counted.

**Table 2**

**ELISA scores of PV-IgG fractions**

<table>
<thead>
<tr>
<th></th>
<th>DSG1 [U/ml]</th>
<th>DSG3 [U/ml]</th>
</tr>
</thead>
<tbody>
<tr>
<td>PV1-IgG</td>
<td>711</td>
<td>5,542</td>
</tr>
<tr>
<td>PV2-IgG</td>
<td>375</td>
<td>11,550</td>
</tr>
</tbody>
</table>
Additional sections were subjected to immunodetection of DSG3 and IgG-Fc as described before (20). AK23 (1:100) was used together with a Cy3-linked goat anti-mouse secondary Ab (1:600; Dianova) to detect murine DSG3. Deposition of IgG was evaluated using the Duolink in situ kit (Olink Bioscience) according to the manufacturer's instructions. The technique is based on the ligation and amplification of DNA oligonucleotides attached to secondary Abs that bind to primary Abs of the 2 proteins of interest. DNA ligation and amplification can only occur if the 2 proteins are in close proximity (<40 nm) and can be detected by fluorescent DNA probes. Primary Abs were used were mouse monoclonal DSG3 Ab (Life Technologies) and rabbit phospho–specific rabbit p38 MAPK pAb (both Cell Signaling), DSG3 pAb (Santa Cruz Biotechnology Inc.), α-tubulin mAb (Abcam), and GAPDH mAb (Sigma-Aldrich). Either a polyclonal, HRP-coupled goat anti rabbit Ab (Cell Signaling) or a goat anti mouse mAb (Dianova) served as secondary Abs. Membranes were developed using the ECL System (GE Healthcare).

**Acknowledgments**

We thank Lisa Bergauer, Tetjana Frantzeskakis, Veronika Heimbach, Claudia Mayerhofer, and Sabine Mühlsimer for excellent technical assistance. Experiments were funded by the Deutsche Forschungsgemeinschaft (SFB 487, TP B5, and SP1300-1).

Received for publication July 22, 2011, and accepted in revised form November 8, 2012.

Address correspondence to: Jens Waschke, Institute of Anatomy and Cell Biology, Pettenkoferstrasse 11, 80336 Munich, Germany. Phone: 49.89.5160.4811; Fax: 49.89.5160.4802; E-mail: jens.waschke@med.uni-muenchen.de.